Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Top Cited Papers
- 15 December 2006
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 108 (13) , 3992-3996
- https://doi.org/10.1182/blood-2006-05-026112
Abstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.Keywords
This publication has 59 references indexed in Scilit:
- Proteasome inhibition in multiple myelomaEuropean Journal Of Cancer, 2006
- Regulation of bone mass by Wnt signalingJournal of Clinical Investigation, 2006
- A role of TRAIL in killing osteoblasts by myeloma cellsThe FASEB Journal, 2006
- Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patientsBlood, 2006
- Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysisBlood, 2004
- New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL)Experimental Hematology, 2004
- Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone diseaseBritish Journal of Haematology, 2003
- Regulation of the osteoblast‐specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathwaysJournal of Cellular Biochemistry, 2003
- The Osteoblast-specific Transcription Factor Cbfa1 Contributes to the Expression of Osteoprotegerin, a Potent Inhibitor of Osteoclast Differentiation and FunctionJournal of Biological Chemistry, 2000
- Production of fibronectin and adherence to fibronectin by human myeloma cell linesBritish Journal of Haematology, 1994